undefined undefined
NaN.000
NaN.00%
JP Morgan analyst Anupam Rama downgrades Rallybio (NASDAQ:RLYB) from Overweight to Neutral.
05-16 00:20
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts jus...
05-14 00:10
Rallybio (NASDAQ:RLYB) filed a prospectus related to the offer and sale of 3.64M shares of common stock. This prospectus is not an offer to sell. Filing More on Rallybio Rallybio shares gain on invest...
05-11 04:15
HC Wainwright & Co. analyst Mitchell Kapoor reiterates Rallybio (NASDAQ:RLYB) with a Buy and maintains $9 price target.
05-10 19:39
Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on...
05-10 12:56
摩根大通证券公司:重申Rallybio(RLYB.US)评级,由优于大市调整至优于大市评级, 目标价8.00美元。
04-19 01:21
Losers: Monogram Orthopaedics (MGRM) -15%. Rallybio Corp (RLYB) -13%. Adial Pharmaceuticals (ADIL) -13%. Lipocine (LPCN) -11%. Bit Origin Ltd (BTOG) -10%. GCT Semiconductor Holding (GCTS) -9%. Eliem T...
04-12 20:32
RLYB隔夜涨82.8%,与强生签署开发协议;MGRM宣布加入英伟达创始计划,隔夜大涨79.3%>>
04-12 19:32
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 250 points on Thursday. The Dow traded up 0.18% to 38,532.50 while the NASDAQ rose 1.63% to 16,433.83. The S&P 500 also rose, gaining, 0.83% to 5,203.26.
04-12 03:21